Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: Triple-negative breast cancer (TNBC) accounts for 10% to 20% of newly diagnosed invasive breast cancer. Finding effective targets for chemotherapy-resistant TNBC has proven difficult in part because of TNBC's molecular heterogeneity. We have previously reported that likely because of the antiapoptotic activity of glucocorticoid receptor (GR) in estrogen receptor (ER)-negative breast epithelial and cancer cells, high GR expression/activity in early-stage TNBC significantly correlates with chemotherapy resistance and increased recurrence. We hypothesized that pretreatment with mifepristone, a GR antagonist, would potentiate the efficacy of chemotherapy in GR+ TNBCs by inhibiting the antiapoptotic signaling pathways of GR and increasing the cytotoxic efficiency of chemotherapy. Experimental Design: TNBC cell apoptosis was examined in the context of physiologic glucocorticoid concentrations, chemotherapy, and/or pharmacologic concentrations of mifepristone. We used high-throughput live microscopy with continuous recording to measure apoptotic cells stained with a fluorescent dye and Western blot analysis to detect caspase-3 and PARP cleavage. The effect of mifepristone on GR-mediated gene expression was also measured. TNBC xenograft studies were performed in female severe combined immunodeficient (SCID) mice and tumors were measured following treatment with vehicle, paclitaxel, or mifepristone/paclitaxel. Results: We found that although mifepristone treatment alone had no significant effect on TNBC cell viability or clonogenicity in the absence of chemotherapy, the addition of mifepristone to dexamethasone/paclitaxel treatment significantly increased cytotoxicity and caspase-3/PARP cleavage. Mifepristone also antagonized GR-induced SGK1 and MKP1/DUSP1 gene expression while significantly augmenting paclitaxel-induced GR+ MDA-MB-231 xenograft tumor shrinkage in vivo. Conclusions: These results suggest that mifepristone pretreatment could be a useful strategy for increasing tumor cell apoptosis in chemotherapy-resistant GR+ TNBC. Clin Cancer Res; 19(22); 6163–72. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 2×
“primary TNBCs identified the NR3C1 (GR-encoding) gene as among the top genes undergoing somatic mutation in association with significant changes in expression of shared GR network genes (24, 25).”
BackgroundCombinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463 · cited 1×
“The glucocorticoid receptor (GR) belongs to a family of nuclear hormone receptors that are ligand-dependent transcription factors involved in activating and repressing gene expression, thereby changing the complement of proteins regulating key signaling pathways (4, 5).”
Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects
WEITZMAN, E. D., FUKUSHIMA, D., NOGEIRE, C., ROFFWARG, H., GALLAGHER, T. F., & HELLMAN, L. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-1-14 · Cited by 1,258
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Lu, N. Z., & Cidlowski, J. A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.025 · Cited by 455 · cited 1×
“Thehighest totalGRmRNAandprotein levelswere found in MDA-MB-231 cells; interestingly, several translational isoforms (GR-A, GR-B, GR-C, GR-D) were also observed in all three cell lines (20, 21).”
BackgroundThe Physiology of Human Glucocorticoid Receptor β (hGRβ) and Glucocorticoid Resistance
LEWIS‐TUFFIN, L. J., & CIDLOWSKI, J. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.001 · Cited by 242
Ubiquitin modification of serum and glucocorticoid-induced protein kinase-1 (SGK-1)
Brickley, D. R., Mikosz, C. A., Hagan, C. R., & Conzen, S. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207604200 · Cited by 94
Self-citationGross, K. L., Oakley, R. H., Scoltock, A. B., Jewell, C. M., & Cidlowski, J. A. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0051 · Cited by 56 · cited 1×
“Thehighest totalGRmRNAandprotein levelswere found in MDA-MB-231 cells; interestingly, several translational isoforms (GR-A, GR-B, GR-C, GR-D) were also observed in all three cell lines (20, 21).”
Background
Cited by
Glucocorticoids promote breast cancer metastasis
Obradović, M. M. S., Hamelin, B., Manevski, N., Couto, J. P., Sethi, A., Coissieux, M.-M., Münst, S., Okamoto, R., Kohler, H., Schmidt, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1019-4 · Cited by 462
Stress and cancer: mechanisms, significance and future directions
Eckerling, A., Ricon-Becker, I., Sorski, L., Sandbank, E., & Ben-Eliyahu, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00395-5 · Cited by 348
Gosain, R., Gage-Bouchard, E., Ambrosone, C., Repasky, E., & Gandhi, S. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00815-y · Cited by 85
Targeting the glucocorticoid receptor in breast and prostate cancers
Kach, J., Conzen, S. D., & Szmulewitz, R. Z. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7531 · Cited by 74
Late glucocorticoid receptor antagonism changes the outcome of adult life stress
Ding, J., da Silva, M. S., Lingeman, J., Chen, X., Shi, Y., Han, F., & Meijer, O. C. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.05.014 · Cited by 26
“It is clear from the clinic and many animal models that GR can contribute to disease processes in many different body systems (Green et al., 2006; Koorneef et al., 2018; Roerink et al., 2016; Skor et al., 2013).”
Metadata
- Authors
- Skor, M. N., Wonder, E. L., Kocherginsky, M., Goyal, A., Hall, B. A., Cai, Y., & Conzen, S. D.
- Venue
- Clinical Cancer Research
- Published
- 2013-11-14
- Volume
- 19
- Issue
- 22
- Pages
- 6163-6172
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2109882948
- Cited by
- 201
- References
- 9
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-3826
- The paper
- Skor, M. N., Wonder, E. L., Kocherginsky, M., Goyal, A., Hall, B. A., Cai, Y., & Conzen, S. D. (2013). Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-3826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.